Compare PLSE & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ADNT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2015 | 2016 |
| Metric | PLSE | ADNT |
|---|---|---|
| Price | $19.11 | $22.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $22.00 | ★ $25.41 |
| AVG Volume (30 Days) | 224.7K | ★ 656.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,439,000,000.00 |
| Revenue This Year | $840.00 | $2.71 |
| Revenue Next Year | $287.54 | $2.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $12.56 | $12.85 |
| 52 Week High | $26.30 | $27.32 |
| Indicator | PLSE | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 57.25 |
| Support Level | $17.32 | $22.01 |
| Resistance Level | $20.40 | $23.89 |
| Average True Range (ATR) | 1.43 | 0.86 |
| MACD | -0.44 | 0.01 |
| Stochastic Oscillator | 13.73 | 67.48 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.